Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Numico ephedra litigation

This article was originally published in The Tan Sheet

Executive Summary

The number of active ephedra cases at both GNC and Rexall Sundown increased by 10 since the beginning of March, "a continuation of the stable trend witnessed over the last 18 months," according to former parent company Royal Numico. The Dutch firm maintains that its occurrence-based insurance policy remains adequate in covering litigation risk, and that the probability of new lawsuits "is less likely" given that it halted ephedra sales last June. Numico reported 137 ephedra liability lawsuits in March (1"The Tan Sheet" March 8, 2004, p. 10)...

You may also be interested in...



GNC Liability In Ephedra Lawsuits Is Limited, Numico Says

Rexall Sundown and GNC have been named in 137 product liability lawsuits involving ephedrine alkaloid-containing dietary supplements, former parent company Royal Numico disclosed in a year-end financials release March 4

Radiation Oncologist Stephen Hahn Wins Final Senate Confirmation As FDA Commissioner

The US Senate on a 72-18 vote approved radiation oncologist Stephen Hahn as Commissioner of the FDA on 12 December. Voting “no” were a block of liberal Democrats, including the ranking member of a key Senate health committee. Industry advocates and most senators said Hahn is an excellent choice to lead the FDA, but some fear he will not move quickly enough to ban candy flavors in vaping products favored by teens.

Iterum Anxiously Awaiting Other Results After SURE 3 Failure

Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.

Topics

UsernamePublicRestriction

Register

PS096807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel